John's Wort.[12] RIF and rifaximin, recognized as potent human PXR agonists, have demonstrated therapeutic efficacy in the treatment of autoimmune skin disease and inflammatory bowel disease, respectively.[13] These findings suggest a promising therapeutic strategy associated with PXR in managing inflammatory or immune‐mediated diseases. The gene discussed is NR1I2; the disease is inflammatory bowel disease.